Zuberitamab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company

Zhejiang BioRay Biopharmaceutical Co., Ltd.

Medicine type

Biologic

Therapeutic area

Oncology

Indications recorded in the public source

For adults with CD20-positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), in combination with standard CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine and prednisone.

Indication source and scope

Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.

Prescribing-information limitations

A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.

China availability status

Historical Chinese approval verified; current continuous market availability has not been checked for every product.

Overseas status

Market-by-market verification pending.

Insurance classification

Included in national insurance (Category B)

Insurance edition

2025 edition; effective 1 January 2026

Insurance restrictions

Restricted to adults with CD20-positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS).

Insurance period

2026-01-01 to 2027-12-31

Insurance verification notes

Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

• https://www.nmpa.gov.cn/directory/web/nmpa/images/1707039824076019627.pdf
• https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
• https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500046/YPSN202500046.pdf

Open the interactive record, public price references and discussions